

February 18, 2016



Maxim Group Hosts Key Opinion Leaders Discussing “Breakthroughs in Dermatology” Relating to Products From Oculus Innovative Sciences

Conference Call on February 25, 2016 at 4:15 pm ET

PETALUMA, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced that Maxim Group analysts, Jason Kolbert and Jason McCarthy, Ph.D., will host a conference call to discuss *Breakthroughs in Dermatology* on February 25, 2016 at 4:15 pm ET.

Key opinions leaders in dermatology will share their perspectives on the science and impact of Oculus' products, including Oculus' Microcyn® Technology, for the treatment of atopic dermatitis, multiple dermatoses, acne and scar management:

Neal D Bhatia, MD,

Director of clinical dermatology at Therapeutics Clinical Research (TCR) Medical Corporation. Previously at Laser Skin Care Center Dermatology Associates and Lakeshore Medical Clinics. Interim program director and associate clinical professor, department of dermatology, Harbor-UCLA Medical Center, with numerous publications, presentations and clinical research projects.

Adam Friedman, MD, FAAD

Associate professor of dermatology, residency program director, and director of translational research, department of dermatology, George Washington School of Medicine and Health Sciences; adjunct assistant professor of medicine (dermatology), and adjunct assistant professor of physiology and biophysics, Albert Einstein College of Medicine. Prior to this he was an instructor of dermatology, Albert Einstein College of Medicine. Dr. Friedman is currently investigating novel therapeutics and delivery systems targeting infectious diseases, accelerating wound healing, immune modulation, and correcting vascular dysfunction. He holds multiple patents derived from these investigations, and has published over 140 papers/chapters and 2 textbooks on both his research as well as a variety of clinical areas in dermatology with an emphasis on emerging medical therapies.

Firas George Hougeir, MD, FAAD

Currently a dermatologist at Douglas Dermatology and Skin Cancer Specialists, Douglasville, Georgia, a member of the editorial board of the *Journal of Cosmetic and Aesthetic Dermatology* as well as president of WFH Medical, LLC. He has also been a board

certified dermatologist at Arizona Dermatology. He adds to his credit board certified dermatologist and Mohs surgeon in Atlanta. He also served as a dermatologist at Family Dermatology in Atlanta. He has completed numerous publications, presentations and research projects.

Individuals interested in participating in the conference call may do so by dialing (877) 303-7607 for domestic callers or (973) 638-3203 for international callers at 4:15 pm ET on Thursday, February 25, 2016.

A telephone replay will be available for seven days following the conclusion of the call by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers and entering conference number 54552618.

About Maxim Group

Founded in 2002, Maxim Group is a leading full-service investment banking, securities and wealth management firm headquartered in New York. Maxim provides a full array of financial services including investment banking, private wealth management, global institutional equity, fixed income and derivative sales and trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals.

About Oculus Innovative Sciences, Inc.

Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "share" and "host," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's common stock and warrants may be delisted from NASDAQ, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, the Company may not be able to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse

regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its annual report on Form 10-K for the year ended March 30, 2015. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Oculus® and Microcyn® Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Oculus Innovative Sciences, Inc.

Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com

[Primary Logo](#)



Source: Oculus Innovative Sciences, Inc.